Free COVID-19 training for Volunteer State volunteers, others around US

Healthcare workers stepping outside their comfort zones to help staff Tennessee’s alternate care facilities are being offered free online training in ventilator safety, infection control and other skills needed during the COVID-19 crisis.

The materials, supplied by Nashville-based HealthStream, are open to staff at healthcare facilities across the U.S.

So far workers in the repurposed response force, whose numbers include the suddenly un-retired, have taken around 200,000 of these courses, according to a company spokesperson.

The training modules draw from HealthStream’s curated collection of courses, with 23 courses available to caregivers everywhere, free of charge, for 90 days.

The company is also offering its customers four key cross-training bundles comprising more than 80 courses.

In announcing the program, HealthStream CEO Robert Frist Jr. says the company’s vision “has always been to improve the quality of healthcare by developing the people who deliver care. … We stand ready to support [Tennessee and] other states and healthcare facilities along with the heroic healthcare professionals who will be delivering care during this most challenging time.”

To browse the courses on offer, click here.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.